Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Impact and Effectiveness of State-level Tuberculosis interventions in California, Florida, New York and Texas: A model-based analysis.

Shrestha S, Cherng S, Hill AN, Reynolds S, Flood J, Barry PM, Readhead A, Oxtoby M, Lauzardo M, Privett T, Marks SM, Dowdy DW.

Am J Epidemiol. 2019 Jun 28. pii: kwz147. doi: 10.1093/aje/kwz147. [Epub ahead of print]

PMID:
31251797
2.

Rifampin-Resistant Tuberculosis In The United States, 1998-2014.

Sharling L, Marks SM, Goodman M, Chorba T, Mase S.

Clin Infect Dis. 2019 Jun 22. pii: ciz491. doi: 10.1093/cid/ciz491. [Epub ahead of print]

PMID:
31233131
3.

Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting.

Schwartzberg LS, Marks SM, Gabrail NY, Geller RB, Kish J.

J Comp Eff Res. 2019 May 9. doi: 10.2217/cer-2018-0104. [Epub ahead of print]

4.

Outlook for tuberculosis elimination in California: An individual-based stochastic model.

Goodell AJ, Shete PB, Vreman R, McCabe D, Porco TC, Barry PM, Flood J, Marks SM, Hill A, Cattamanchi A, Kahn JG.

PLoS One. 2019 Apr 9;14(4):e0214532. doi: 10.1371/journal.pone.0214532. eCollection 2019.

5.

Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.

Tsang CA, Shah N, Armstrong LR, Marks SM.

Clin Infect Dis. 2019 Apr 4. pii: ciz263. doi: 10.1093/cid/ciz263. [Epub ahead of print]

PMID:
30944927
6.

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness.

Nwana N, Marks SM, Lan E, Chang AH, Holcombe M, Morris SB.

PLoS One. 2019 Mar 13;14(3):e0213524. doi: 10.1371/journal.pone.0213524. eCollection 2019.

7.

The Impact of HIV Infection on TB Disparities Among US-Born Black and White Tuberculosis Patients in the United States.

Marks SM, Katz DJ, Davidow AL, Pagaoa MA, Teeter LD, Graviss EA.

J Public Health Manag Pract. 2019 Feb 14. doi: 10.1097/PHH.0000000000000949. [Epub ahead of print]

PMID:
30789591
8.

Number and cost of hospitalizations with principal and secondary diagnoses of tuberculosis, United States.

Aslam MV, Owusu-Edusei K, Marks SM, Asay GRB, Miramontes R, Kolasa M, Winston CA, Dietz PM.

Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1495-1504. doi: 10.5588/ijtld.18.0260.

PMID:
30606323
9.

Tuberculosis Incidence Among Populations at High Risk in California, Florida, New York, and Texas, 2011-2015.

Cherng ST, Shrestha S, Reynolds S, Hill AN, Marks SM, Kelly J, Dowdy DW.

Am J Public Health. 2018 Nov;108(S4):S311-S314. doi: 10.2105/AJPH.2018.304503.

10.

Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy.

Schwartzberg LS, McLaughlin T, Geller RB, Gabrail NY, Marks SM.

J Comp Eff Res. 2018 Dec;7(12):1161-1170. doi: 10.2217/cer-2018-0089. Epub 2018 Oct 11.

11.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

PMID:
30215381
12.

Antifreeze protein hydration waters: Unstructured unless bound to ice.

Marks SM, Patel AJ.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8244-8246. doi: 10.1073/pnas.1810812115. Epub 2018 Aug 6. No abstract available.

13.

Yield of testing and treatment for tuberculosis among foreign-born persons during contact investigations in the United States: A semi-systematic review.

Parriott A, Malekinejad M, Miller AP, Horvath H, Marks SM, Kahn JG.

PLoS One. 2018 Jul 19;13(7):e0200485. doi: 10.1371/journal.pone.0200485. eCollection 2018.

14.

Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model.

Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA.

Am J Epidemiol. 2018 Sep 1;187(9):2011-2020. doi: 10.1093/aje/kwy094.

PMID:
29762657
15.

Care Cascade for targeted tuberculosis testing and linkage to Care in Homeless Populations in the United States: a meta-analysis.

Parriott A, Malekinejad M, Miller AP, Marks SM, Horvath H, Kahn JG.

BMC Public Health. 2018 Apr 12;18(1):485. doi: 10.1186/s12889-018-5393-x.

16.

Tuberculosis Test Usage and Medical Expenditures from Outpatient Insurance Claims Data, 2013.

Owusu-Edusei K Jr, Winston CA, Marks SM, Langer AJ, Miramontes R.

Tuberc Res Treat. 2017;2017:3816432. doi: 10.1155/2017/3816432. Epub 2017 Oct 23.

17.

Mixed Reality with HoloLens: Where Virtual Reality Meets Augmented Reality in the Operating Room.

Tepper OM, Rudy HL, Lefkowitz A, Weimer KA, Marks SM, Stern CS, Garfein ES.

Plast Reconstr Surg. 2017 Nov;140(5):1066-1070. doi: 10.1097/PRS.0000000000003802.

PMID:
29068946
18.

Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.

Tasillo A, Salomon JA, Trikalinos TA, Horsburgh CR Jr, Marks SM, Linas BP.

JAMA Intern Med. 2017 Dec 1;177(12):1755-1764. doi: 10.1001/jamainternmed.2017.3941.

19.

Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly.

Vogel JW, Varga Doležalová M, La Joie R, Marks SM, Schwimmer HD, Landau SM, Jagust WJ.

Neurology. 2017 Nov 7;89(19):2002-2009. doi: 10.1212/WNL.0000000000004627. Epub 2017 Oct 6.

20.

Yield of community-based tuberculosis targeted testing and treatment in foreign-born populations in the United States: A systematic review.

Malekinejad M, Parriott A, Viitanen AP, Horvath H, Marks SM, Kahn JG.

PLoS One. 2017 Aug 7;12(8):e0180707. doi: 10.1371/journal.pone.0180707. eCollection 2017. Review.

21.

Comparing Drivers and Dynamics of Tuberculosis in California, Florida, New York, and Texas.

Shrestha S, Hill AN, Marks SM, Dowdy DW.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):1050-1059. doi: 10.1164/rccm.201702-0377OC.

22.

The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States.

Vargo JA, Patel A, Glaser SM, Balasubramani GK, Farah RJ, Marks SM, Beriwal S.

Cancer. 2017 Aug 15;123(16):3176-3185. doi: 10.1002/cncr.30697. Epub 2017 Apr 5.

23.
24.

Outcomes and costs of out-patient MDR-TB care in the USA.

Marks SM, Hirsch-Moverman Y, Seaworth B, Salcedo K, Graviss EA, Armstrong L, Armitige L, Flood J, Mase S.

Int J Tuberc Lung Dis. 2017 Apr 1;21(4):477-478. doi: 10.5588/ijtld.17.0009. No abstract available.

25.

Tuberculosis hospitalization expenditures per patient from private health insurance claims data, 2010-2014.

Owusu-Edusei K, Marks SM, Miramontes R, Stockbridge EL, Winston CA.

Int J Tuberc Lung Dis. 2017 Apr 1;21(4):398-404. doi: 10.5588/ijtld.16.0587. Erratum in: Int J Tuberc Lung Dis. 2017 Jul 1;21(7):834.

26.

Tau and β-Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging.

Marks SM, Lockhart SN, Baker SL, Jagust WJ.

J Neurosci. 2017 Mar 22;37(12):3192-3201. doi: 10.1523/JNEUROSCI.3769-16.2017. Epub 2017 Feb 17.

27.

In reply.

Castro KG, Marks SM, Hill AN, Chen MP, Miramontes R, Winston CA, LoBue PA.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):120-121. doi: 10.5588/ijtld.16.0708-2. No abstract available.

28.

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.

Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA.

Neuromuscul Disord. 2017 Mar;27(3):266-268. doi: 10.1016/j.nmd.2017.01.002. Epub 2017 Jan 6. Review.

PMID:
28109638
29.

Aging Affects Dopaminergic Neural Mechanisms of Cognitive Flexibility.

Berry AS, Shah VD, Baker SL, Vogel JW, O'Neil JP, Janabi M, Schwimmer HD, Marks SM, Jagust WJ.

J Neurosci. 2016 Dec 14;36(50):12559-12569. Epub 2016 Nov 2.

30.

Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades.

Castro KG, Marks SM, Chen MP, Hill AN, Becerra JE, Miramontes R, Winston CA, Navin TR, Pratt RH, Young KH, LoBue PA.

Int J Tuberc Lung Dis. 2016 Jul;20(7):926-33. doi: 10.5588/ijtld.15.1001.

31.

Impact of lifestyle dimensions on brain pathology and cognition.

Schreiber S, Vogel J, Schwimmer HD, Marks SM, Schreiber F, Jagust W.

Neurobiol Aging. 2016 Apr;40:164-172. doi: 10.1016/j.neurobiolaging.2016.01.012. Epub 2016 Jan 30.

32.

Characteristics and costs of multidrug-resistant tuberculosis in-patient care in the United States, 2005-2007.

Marks SM, Hirsch-Moverman Y, Salcedo K, Graviss EA, Oh P, Seaworth B, Flood J, Armstrong L, Armitige L, Mase S; TB Epidemiologic Studies Consortium.

Int J Tuberc Lung Dis. 2016 Apr;20(4):435-41. doi: 10.5588/ijtld.15.0575.

33.

Risk factors for transmission of tuberculosis among United States-born African Americans and Whites.

Pagaoa MA, Royce RA, Chen MP, Golub JE, Davidow AL, Hirsch-Moverman Y, Marks SM, Teeter LD, Thickstun PM, Katz DJ; Tuberculosis Epidemiologic Studies Consortium.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1485-92. doi: 10.5588/ijtld.14.0965.

34.

Tuberculosis Elimination Efforts in the United States in the Era of Insurance Expansion and the Affordable Care Act.

Balaban V, Marks SM, Etkind SC, Katz DJ, Higashi J, Flood J, Cronin A, Ho CS, Khan A, Chorba T.

Public Health Rep. 2015 Jul-Aug;130(4):349-54.

35.

β-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation.

Mander BA, Marks SM, Vogel JW, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP.

Nat Neurosci. 2015 Jul;18(7):1051-7. doi: 10.1038/nn.4035. Epub 2015 Jun 1.

36.

Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.

Lim SJ, Lim MJ, Raptis A, Hou JZ, Farah R, Marks SM, Im A, Dorritie K, Sehgal A, Agha M, Felgar R, Lim SH.

Am J Hematol. 2015 Aug;90(8):715-8. doi: 10.1002/ajh.24062.

37.

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, DeCarli C, Seeley WW, Jagust W.

Brain. 2015 Jul;138(Pt 7):2020-33. doi: 10.1093/brain/awv112. Epub 2015 May 6.

38.

Effects of Beta-Amyloid on Resting State Functional Connectivity Within and Between Networks Reflect Known Patterns of Regional Vulnerability.

Elman JA, Madison CM, Baker SL, Vogel JW, Marks SM, Crowley S, O'Neil JP, Jagust WJ.

Cereb Cortex. 2016 Feb;26(2):695-707. doi: 10.1093/cercor/bhu259. Epub 2014 Nov 7.

39.

Neural compensation in older people with brain amyloid-β deposition.

Elman JA, Oh H, Madison CM, Baker SL, Vogel JW, Marks SM, Crowley S, O'Neil JP, Jagust WJ.

Nat Neurosci. 2014 Oct;17(10):1316-8. doi: 10.1038/nn.3806. Epub 2014 Sep 14.

40.

Opportunities for tuberculosis diagnosis and prevention among persons living with HIV: a cross-sectional study of policies and practices at four large Ryan White Program-Funded HIV clinics.

Pascopella L, Franks J, Marks SM, Salcedo K, Schmitz K, Colson PW, Hirsch-Moverman Y, Flood J, Sayles J.

PLoS One. 2014 Jul 7;9(7):e101313. doi: 10.1371/journal.pone.0101313. eCollection 2014.

41.

Gene-environment interactions: lifetime cognitive activity, APOE genotype, and β-amyloid burden.

Wirth M, Villeneuve S, La Joie R, Marks SM, Jagust WJ.

J Neurosci. 2014 Jun 18;34(25):8612-7. doi: 10.1523/JNEUROSCI.4612-13.2014.

42.

Iatrogenic vertebral artery injury secondary to vessel tortuosity in a grossly degenerate cervical spine.

Khan SA, Coulter I, Marks SM.

Br J Neurosurg. 2014 Jun;28(3):423-5. doi: 10.3109/02688697.2014.913772. Epub 2014 May 8.

PMID:
24810983
43.

Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.

Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, Armitige L, Revuelta M, Sheeran K; TB Epidemiologic Studies Consortium.

Emerg Infect Dis. 2014 May;20(5):812-21. doi: 10.3201/eid2005.131037.

44.

Timely HIV diagnosis and HIV/TB comanagement among California patients in 2008.

Kong D, Watt JP, Marks SM, Flood JM.

Public Health Rep. 2014 Mar-Apr;129(2):170-7.

45.

Chiari I malformation associated with Gorham's disease of the skull base.

Coulter IC, Khan SA, Flanagan AM, Marks SM.

Clin Neurol Neurosurg. 2014 Jan;116:83-6. doi: 10.1016/j.clineuro.2013.11.007. Epub 2013 Nov 16. No abstract available.

PMID:
24300744
46.

Economics of United States tuberculosis airline contact investigation policies: a return on investment analysis.

Coleman MS, Marienau KJ, Marano N, Marks SM, Cetron MS.

Travel Med Infect Dis. 2014 Jan-Feb;12(1):63-71. doi: 10.1016/j.tmaid.2013.10.016. Epub 2013 Nov 8.

47.

Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.

Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR.

Int J Tuberc Lung Dis. 2013 Dec;17(12):1531-7. doi: 10.5588/ijtld.13.0423.

48.

The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States.

Marks SM, Cronin W, Venkatappa T, Maltas G, Chon S, Sharnprapai S, Gaeddert M, Tapia J, Dorman SE, Etkind S, Crosby C, Blumberg HM, Bernardo J.

Clin Infect Dis. 2013 Aug;57(4):532-42. doi: 10.1093/cid/cit336. Epub 2013 May 22.

49.

Second hand smoke and COPD: lessons from animal studies.

Goldklang MP, Marks SM, D'Armiento JM.

Front Physiol. 2013 Feb 27;4:30. doi: 10.3389/fphys.2013.00030. eCollection 2013.

50.

Association of lifetime cognitive engagement and low β-amyloid deposition.

Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H, O'Neil JP, Wilson RS, Jagust WJ.

Arch Neurol. 2012 May;69(5):623-29.

Supplemental Content

Loading ...
Support Center